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Vitamin B6 deficiency in uremia and its implications for the
depression of immune responses. By serial determinations of the
glutamic oxaloacetic transaminase (GOT) activity of erythro-
cytes, we found a marked biochemical vitamin B6 deficiency in
48 out of 69 patients with advanced chronic azotemia (serum
creatinine >4 mg/lOO ml), 37 on chronic intermittent dialysis
and 32 being treated conservatively. As an index for vitamin B6
status, we used the stimulation effect of pyridoxal-5' phosphate
on the erythrocyte EGOT activity (activation coefficient,
aEGop), with values 1.7 indicating a biochemical vitamin B6
deficiency. Increased activation coefficients were restored to
normal by the oral administration of 300 mg of vitamin B6
(pyridoxine HCI) daily for two weeks. From measurements of
the GOT activity of nondeficient erythrocytes after incubation
with plasma of uremic patients, we can exclude any inhibitory
effect of plasma constituents in uremia on the enzyme activity.
Hemodialysis improved elevated EGOT ratios significantly. On
the basis of these findings we suggest that inhibition of pyridoxal
kinase activity rather than insufficient vitamin B6 supply is the
most likely explanation for the depletion of vitamin B6 coenzyme
in uremia. Diminution of reactivity in mixed lymphocyte
cultures of uremics could be reversed by treating the patients
with vitamin B6 orally. We conclude that suppression of cell-
mediated immunity in uremia is probably in part due to vitamin
B6 depletion.
Deficit en vitamine B6 dans l'urémie et ses implications quant
a la diminution des responses immunes. Au moyen de détermina-
tions répétées de la transaminase glutamate-oxaloacétique
(GOT) des érythrocytes nous avons mis en evidence un deficit
important en vitamine B6 chez 48 malades parmi 69 atteints
d'insuffisance rénale chronique (créatininémie>4 mg/100 ml), 37
d'entre eux sont soumis a l'hémodialyse périodique et 32 sont
traités par des moyens conservateurs. Comme paramétre de la
situation de la vitamine B6 nous utilisons l'effet stimulateur du
pyridoxal-5' phosphate sur l'activité de la transaminase
glutamate-oxaloacétique des érythrocytes (coefficient d'activa-
tion xEGOT), des valeurs 1,7 indiquent un deficit biochimique
en vitamine B6. Des coefficients d'activation augmentés sont
normalisés par l'administration orale de 300 mg de vitamine B6
quotidiennement pendant deux semaines. A partir de mesures de
l'activité de Ia GOT d'erythrocytes sans deficit incubés avec du
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plasma de malades urémiques nous pouvons exciure un quel-
conque effet inhibiteur des constituants plasmatiques au cours
de l'urémie sur l'activité enzymatique. Sur la base de ces con-
stations nous suggérons que l'inhibition de l'activité de la
pyridoxal-kinase, plutôt qu'un apport insuffisant de vitamine
B6, est l'explication la plus probable de la déplétion en coenzyme
de la vitamine B6 au cours de l'urémie. La diminution de réac-
tivité de cultures mixtes de lymphocytes d'urémiques pourrait
être abolie par le traitement préalable des malades par la
vitamine B6. Nous concluons que la suppression de l'immunité
cellulaire au cours de l'urémie est probablement en partie liée a
une déplétion en vitamine B6.
Clinical abnormalities such as anemia, neurological
disorders, osteomalacia and hypocalcemia in patients
undergoing intermittent hemodialysis have been con-
sidered to be associated with vitamin deficiencies for
more than ten years [1]. Dietary restrictions, impaired
intestinal absorption [2] and losses during dialysis
have been incriminated as causes for the vitamin de-
ficiencies.
Lasker, Harvey and Baker [3] measured different
vitamins of the B group in six patients on intermittent
dialysis and found only low nicotinic and folic acid
concentrations. They did not, however, determine
vitamin B6, probably because deficiencies of this
vitamin had traditionally been investigated by means of
the tryptophan loading test and, because of falsely iow
xanthurenic acid excretion as a consequence of changes
in tryptophan metabolism [4], this test could not be
used in patients with renal failure.
Since a number of comparable clinical symptoms
and biochemical alterations may be found in both
uremia and vitamin B6 deficiency—convulsions,
peripheral neuropathy, normochromic anemia, de-
pression of immune responses, changes in the plasma
amino acid pattern [4—111—we thought it worthwhile
to investigate the vitamin B6 status in patients with
chronic renal failure.
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Methods
Analyticaiprocedure for the assessment of the vitamin
B6 status. Vitamin B6 status was determined by
measuring the activity of erythrocyte glutamic
oxaloacetic transaminase (EGOT; aspartate 2-oxo-
glutarate aminotransferase E.C. 2.6.1.1) and the de-
gree of its stimulation by incubating with pyridoxal-5'
phosphate (PALP). The oxaloacetate, resulting from
the transamination reaction, is enzymatically con-
verted to malate by malate dehydrogenase. Since this
enzyme depends on nicotinamide adenine dinucleotide
(NADH), the consumption of NADH, ascertained by
measuring the decrease of absorption at 334 nm,
corresponds to the amount of oxaloacetate formed,
which in turn reflects the degree of EGOT activity [12].
The stimulation effect of PALP, expressed as activa-
tion coefficient CZEGOT, is calculated by dividing the
substrate turnover with added PALP by substrate
turnover without adding the coenzyme [13] (Table I).
Activation coefficients 1.70 (average+2.5 SD) indi-
cate a biochemical vitamin B6 deficiency [7].
Patients studied, a) in 37 patients treated with
chronic intermittent hemodialysis, EGOT activation
coefficients were repeatedly assessed over a period of
several months. b) Additionally, in 19 patients enzyme
activities were determined before and after an eight-
hour period of hemodialysis (using Twin Coil UF 100
dialyzers) (Fig. I). c) EGOT ratios were also assessed
in 32 patients with chronic renal insufficiency (serum
creatinine values ranging between 4 and 18 mg/100 ml;
mean, 9.08 4.29) who were treated conservatively
with dietary protein restriction (0.5 g of protein/kg of
body weight daily) (Table 2) and in 12 patients with
EGOT01040•20hct — =EGOT00 [IUB-units]
(= turnover of I mole of substrate• liter 1
mm 1 at 25°C)
EGOT01 = Units read from recorder diagram
EGOTO = Units without PALP5 incubation
EGOT+ = Units with PALP incubation
hct = Hematocrit of the cell suspension
40
= Conversion factor for hematocrit 40%
20 = Dilution factor of the hemolysate
Activation coefficient (PALP stimulation)
EGOTO
cOEGOT =EGOT+
Fig. 1. Values of aEGOT and mean SD before and after hemo-
dialysis (P< 0.01, N= 19).
acute renal failure within ten days after onset, in-
cluding two patients with septicemia and eclampsia
(mean serum creatinine, 8.5 mg/100 ml 1.54). d) The
effect of oral administration of vitamin B6 in daily
doses of 300 mg for two weeks was studied in 12
patients treated by intermittent hemodialysis and in
three patients on conservative treatment (Fig. 2). e)
Erythrocytes and hemolysate of erythrocytes of
apparently healthy people were incubated for 30
minutes at 37°C with plasma of uremic patients with
high aEG0T values to check the possibility of an
influence of uremic toxins on transaminase activities.
Procedure fr the assessment of the cellular immune
response. We used mixed lymphocyte cultures (MLC)
to measure cellular immune responses. MLC's were
produced according to the method of Bach, Solliday
and Stambuk [14]. Leukocytes were prepared from
heparinized blood (100 U/mI) by sedimentation of the
erythrocytes and spinning down the leukocyte-rich
supernatant. The autologous plasma was discarded.
The leukocytes were washed once in culture medium
(TC 199). No attempt was made to separate lympho-
cytes from grariulocytes. Then, 0.75 x 106 responding
lymphocytes were mixed with 1 x 106 mitomycin-C
treated stimulating cells in culture medium (TC 199),
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Table 1. Calculation of the activation coefficient (erGoT) in
washed erythrocytes
° Erythrocyte glutamic oxaloacetic transaminase (EGOT) ac-
tivity is based on 1 liter of cell suspension at a hematocrit (hct)
value of 40%.
b PALP= pyridoxal-5'-phosphate.
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Table 2. aEGOT in patients with chronic renal failure receiving
conservative treatment6
Patient
No.
aEGOT Serum
creatinine,
mg/lOU ml
Patient
No.
aEGOT Serum
creatinine,
mg/l0O ml
1 2.77 18.2 17 1.69 8.0
2 1.55 17.6 18 1.71 7.9
3 2.87 17.3 19 1.43 7.8
4 1.40 15.6 20 1.77 7.7
5 1.86 15.0 21 1.79 7.7
6 2.16 13.1 22 2.00 7.2
7 2.41 13.0 23 1.92 7.2
8 2.83 12.8 24 1.98 6.3
9 1.73 12.5 25 2.01 6.8
10 1.72 11.1 26 1.80 6.0
11 1.87 10.2 27 1.92 5.3
12 2.29 10.0 28 1.36 5.2
13 1.70 10.1 29 1.88 4.1
14 1.40 9.9 30 1.44 4.0
15 1.23 9.1 31 1.93 4.0
16 2.68 8.7 32 2.30 3.9
The individuals are listed according to their serum creatinine
concentrations. There is no correlation between creatinine and
aEGoT values. aEGOTx= 1.93 0.43 (SD); creatinine (mg/100 ml)
x= 9.08 4.29 (SD); aEGOT 1.7: definite biochemical vitamin
86 deficiency.
supplemented with 15 stored antibody-free blood-
bank AB serum, penicillin, streptomycin and HEPES-
buffer. Similarly, phytohemagglutinin (PHA)-stimu-
lated cells and the same amount of responding cells
were mixed with 1.0 ml of medium containing 0.01
mg/liter PHA-M (Welicome). In view of the shortened
half-life of uremic lymphocytes [11] and our own ex-
perience that stimulation ratios often decline after the
fourth day, we chose a culture period of 96 hours, as
usual in our routine MLC program and as recom-
mended by Bach et al [14]. Sixteen hours before har-
vesting, 2 Ci of 3H-thymidine was added to each
EGOT
Fig. 2. Values for a6GOT in patients with chronic uremia before and
after oral administration of vitamin B6 (300 mg daily for two
weeks).
culture tube. Deoxyribonucleic acid (DNA) was pre-
cipitated on glass-fiber filters with 5% ice-cold trichlor-
acetic acid (TCA). When the filters were dry, we added
scintillation fluid and measured the radioactivity in a
scintillation counter (Packard). All tests were done in
triplicate and the results expressed either as counts per
minute (cpm)/culture tube or as stimulation ratio.
These ratios were calculated from the cpm of the ex-
perimental cell mixture divided by the cpm of the
responding cells cultured in the medium alone. The
details of this procedure are described elsewhere [15].
The control persons were healthy blood donors selected
only for HL-A antigens.
Patients studied. a) We produced MLC's from 45
patients in our intermittent hemodialysis program and
compared the stimulation ratios with those of 314
normal individuals (Fig. 3). b) In order to test whether
additional vitamin B6 would increase the stimulation
ratio of lymphocytes, we doubled the pyridoxine
hydrochloride concentration in the culture medium,
i.e., 0.1 mg/liter instead of 0.05 mg/liter, as usually
used, and compared the effect in 25 identical samples.
c) Fourteen patients with chronic azotemia and show-
ing a biochemical vitamin B6 deficiency were adminis-
tered 300 mg of pyridoxine hydrochloride daily for
two weeks. Before and after treatment the cells of
these patients were tested by the standard MLC
procedure (Fig. 4). In addition, the effect of incubation
with additional pyridoxine hydrochloride was in-
vestigated in five patients of this group.
Results
The mean aEG0T value in 37 patients treated with
intermittent hemodialysis was 1.84 0.31 (range, 1.29
to 2.88). Twenty-five patients showed values 1.70.
In 32 uremic patients treated conservatively, the cor-
responding mean aEGOT = 1.93 0.43 (range, 1.23 to
2.87), and 24 of them were biochemically vitamin B6-
deficient (Table 2). There was no correlation between
plasma creatinine concentrations and aEGOT values. In
contrast, only three of 12 patients (mean aEQOT, 1.62
0.20) suffering from acute renal failure showed aEaoT
values 1.70, but in two of these patients other reasons
norma (late pregnancy, septicemia) could also have been
responsible for this biochemical abnormality. EGOT-
activation coefficients following dialysis were lower
than predialysis values in 18 of the 19 patients examined
(Fig. 1). The mean decrease amounted to 12%, which
was highly significant (P<0.0l, t test for paired
samples). After orally administered vitamin B6 treat-
ment of 14 patients with chronic uremia, 13 of them
showing a biochemical vitamin B6 deficiency, all
t t
Before After 5—8 weeks laterN=14 N=15 N=l1
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aEGOT values were within the normal range (<1.70).
In the majority of patients the EGOT ratios again
reached deficient values five to eight weeks after dis-
continuation of the vitamin B6 supply (Fig. 2). Incuba-
tion for 30 minutes at 37°C of either washed erythro-
cytes of healthy individuals or of the corresponding
hemolysates with plasma from uremic patients with
deficient GEGOT values did not influence the EGOT
activity, thus excluding any inhibitory effect of uremic
toxins.
As already shown by other groups [11, 16—191
lymphocyte stimulation ratios against "unrelated
controls" in the MLC were consistently and sig-
nificantly (P < 0.001) lower in uremic patients than in
healthy individuals (Fig. 3). When applying the MLC
procedure to the same sample, doubling only the
vitamin B6 concentration of the culture medium, no
significant rise in the stimulation ratios was found in
IV=13 N=l3
P <0.02
Fig. 4. Stimulation ratios in mixed lymphocyte cultures of uremic
patients before and after two weeks of treatment with 300 mg of
vitamin B6 daily. Dots represent ratios of individual samples
(done in triplicate); bars indicate mean values SD (a <0.02).
(One patient with a 15-fold increase in ratio was not included in
the figure and statistics.)
the samples with the higher vitamin B8 concentration
(mean value = 7.69 vs. 7.43 using the lower pyridoxine
concentration in the culture medium). Cells of patients
with high a6GOT values submitted to the MLC pro-
cedure before and after oral administration of 300 mg
of vitamin B6 daily for two weeks (Fig. 4, Table 3)
showed a significant rise in stimulation ratios (a =0.02,
Wilcoxon matched-pairs signed-ranks test). In the five
cases in which we tested the effect of an increased
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Fig. 3. Stimulation ratios in mixed lymphocyte cultures of uremie
patients and healthy individuals. AO = responding cells, Xm =
mitomycin treated stimulating cells of "unrelated controls."
Stimulation ratios are calculated from counts per minute (cpm)
of the cell mixture AXm divided by AO (see Methods). Dots
represent ratios (done in triplicate) of single patients; bars
indicate mean±so (P<0.001).
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Table 3. Mixed lymphocyte culture (MLC) stimulation results
(in counts per minute, cpm) of uremic patients before and after
treatment with orally administered vitamin B60
Patient
No.
Before In vivo tre
cpm
atrnent, After in vivo tre
cpm
atment,
A0 AXm Xo A0 Axm X0
1 1.334 14.101 2208 399 3812 545
2 12.848 31.362 2208 5041 8.153 545
3 3.128 6.325 253 598 4.152 911
4 3.449 18.175 2208 2247 29.382 545
5 2.514 14.407 2208 867 6318 545
6 540 2.027 458 150 1215 159
7 375 2.677 458 309 1904 159
8 435 3.058 439 554 8083 231
9 313 1.605 439 248 2021 231
10 845 4.539 644 707 6940 708
11 2.522 21.607 1070 6502 37.003 1337
12 730 5.009 810 1616 18.139 1337
13 2.569 10.563 993 478 3674 708
14 1.497 23.379 3265 573 24.721 1322
o A0, autologous control (patient); X0, autologous control (nor-
mal person); AXm, mixture of patient cells with mitomycin C
treated control cells.
vitamin B6 concentration in the culture medium
(0.1 mg1iter) after two weeks of oral administration of
vitamin B6, the lymphocyte stimulation ratio was
higher than that of cells grown in a culture medium
containing the usual concentration of 0.5 mg/liter of
pyridoxine hydrochloride (Table 4).
Discussion
Our investigations using the EGOT activation test
showed that patients with chronic azotemia tend to
develop vitamin B6 deficiency which can be corrected
by oral administration of pyridoxine hydrochloride.
Findings of investigations before and after hemodialy-
sis lead to the assumption that uremic toxins could
interfere with vitamin B6 or vitamin B6-dependent
enzymes. Findings in "normal" erythrocytes after
incubation with plasma of patients suffering from
chronic renal disease, and in red blood cells of patients
with acute renal failure, however, exclude an inhibitory
effect of uremic toxins on the vitamin B. coenzyme in
erythrocytes: I) plasma of patients with chronic renal
failure and high EGOT activation values did not
influence the EGOT activity of "normal" erythro-
cytes; 2) patients with acute renal failure and marked
azotemia showed deficient aEGOT values only when
other conditions (e.g., late pregnancy, septicemia)
influencing vitamin B6 metabolism were present.
Table 4. Stimulation ratio resulting from different
in vitro concentrations of vitamin B6 after two weeks
of B6 treatment in vitro
Patient
No.
Vitamin B6,
0.05 mg/liter
Vitamin B5,
0.1 mg/liter
1 9.8 12.2
2 5.5 6.2
3 11.2 13.0
4 7.5 10.3
5 43.1 60.7
As an attempt to explain these findings, we propose
the following tentative hypothesis as a basis for dis-
cussion: uremic toxins exert an inhibitory effect not on
the vitamin B. or PALP itself, but rather on pyridoxal
kinase, the intracellular enzyme responsible for the
phosphorylation of pyridoxal and its analogues [20—
22]. This would explain why the plasma of uremic
patients does not affect the EGOT activity of "normal"
erythrocytes and why patients with acute renal failure
usually show EGOT activation coefficients which are
within the normal range. If the preformed intracellular
stores of pyridoxal phosphate are not inhibited by
uremic toxins and only the neoformation of pyridoxal
phosphate is affected by the inhibition of the pyridoxal
kinase, then—in analogy to dietary vitamin B6 de-
ficiency—it would take several weeks until a bio-
chemical depletion of the vitamin B. coenzyme
develops. This is what we found after the deficiency
was corrected by oral treatment. That only high doses
of vitamin B6 restored pyridoxal-5' phosphate con-
centrations to normal could be explained by the fact
that pyridoxal kinase activity is substrate dependent
[20]. On the other hand, the positive effect of hemo-
dialysis could be due to a reactivation of pyridoxal
kinase by removal of inhibiting toxins. Whether de-
pressed intestinal absorption of pyridoxine or im-
paired transport through the cell membrane may play
an additional role in the genesis of vitamin B6 deple-
tion in uremia remains open to further investigations.
The question then arises whether there are bio-
chemical and clinical consequences of vitamin B6
depletion in uremia. Pyridoxal-5' phosphate is an
essential coenzyme for the metabolism of amino
acids [5, 8, 23]. It is also necessary for antibody
formation and the integrity of the cellular immune
responses [7, 10, 24]; suppression of delayed hyper-
sensitivity reactions is a typical observation in uremia
as well as in vitamin B6 deficiency [24, 25]. Low
stimulation ratios in the MLC are good indexes to
measure changes in the delayed hypersensitivity
reaction [11, 23].
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Our own MLC results in uremic patients are in
agreement with other published findings [11, 16—18].
The underlying mechanism for the low stimulation
ratios has been discussed but not explained satis-
factorily. Daniels et a! [11] explained the low stimula-
tion ratios on the basis of high spontaneous 3H-
thymidine incorporation which influences the ratio:
specific stimulationjautologous transformation. Even
though this is true in some of our patients (Table 3),
most of the cultures had an autologous cpm not
differing from that of the normal controls. In addition,
those cultures with high spontaneous transformation
rarely manifested a low stimulation ratio. Because it
was shown by Johnson et a! [26] that high granulocyte
counts influence the MLC reaction, patients with
bacterial infections were excluded from our study. It
is not very likely, however, that spontaneous granu-
locytosis is responsible for the low stimulation ratios
in uremia.
According to our findings, vitamin B6 depletion
seems to be responsible, to a certain degree, for the
low stimulation effects. The mechanism of this in-
fluence is unknown. As MLC stimulation depends on
the number of T cells susceptible for a given difference
at the MLC locus, it is possible that either this pool is
diminished in the vitamin B6-depleted patient and in-
creases after two weeks of oral treatment, or that the
shortened life span of the lymphocytes found by
Daniels et al [11] increases with vitamin supplementa-
tion. Because of the marked anemia of the patients it
was not possible to do kinetic studies.
In vitro supplementation with pyridoxine hydro-
chloride of the culture medium without preceding
vitamin B6 treatment of the patients was insufficient
to produce this effect.
Since the results from the MLC measurements
correlate well with tissue graft rejections, it seems
possible that the greater tolerance of uremic patients
towards tissue transplants is in part due to vitamin B6
depletion.
Reprint requests to Dr. II. Dobbe/stein, I. Medizinische Klinik
der Universität Munchen, Ziemssenstrasse 1, D-8 München 2,
West Germany.
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